Valuation: INSTITUT

Market Cap 4.4B 53.54M 46.49M 43.4M 39.62M 74.58M 5.12B 76M 509M 200M 2.56B 202M 197M 8.48B P/E 2024
25.7x
P/E 2025 46.2x
Enterprise Value 4.64B 56.39M 48.97M 45.71M 41.73M 78.56M 5.39B 80.05M 536M 210M 2.7B 212M 207M 8.93B EV / Sales 2024
3.02x
EV / Sales 2025 2.7x
Free-Float
17.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Investment Officer - -
Director TitleAgeSince
Director/Board Member 68 23/08/2010
Director/Board Member 47 09/01/2014
Director/Board Member 45 01/01/2011
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%-8.36%+50.52%+29.48% 122B
+1.09%+2.68%+10.72%+51.65% 89.49B
+0.81%+5.71%+11.31%+66.88% 30.64B
-0.06%+2.29%+36.77%+74.47% 26.31B
-2.13%-0.26%-11.21%-16.82% 21.85B
+2.14%+2.88%+60.40%+246.27% 21.11B
-0.41%-2.08%-5.52%-2.05% 14.65B
+0.41%-5.40%+2.76%-10.57% 12.88B
+1.72%-23.46%+43.92%+63.09% 11.72B
Average +0.34%-2.89%+22.19%+55.82% 39.01B
Weighted average by Cap. +0.21%-2.47%+28.36%+50.26%

Financials

2024 2025
Net sales 1.52B 18.51M 16.07M 15M 13.7M 25.78M 1.77B 26.27M 176M 69.01M 887M 69.73M 67.98M 2.93B 1.72B 20.88M 18.13M 16.92M 15.45M 29.08M 1.99B 29.64M 199M 77.85M 1B 78.65M 76.68M 3.31B
Net income 215M 2.61M 2.27M 2.12M 1.93M 3.64M 250M 3.71M 24.87M 9.75M 125M 9.85M 9.6M 414M 96.95M 1.18M 1.02M 956K 873K 1.64M 113M 1.67M 11.22M 4.4M 56.49M 4.44M 4.33M 187M
Net Debt 199M 2.42M 2.1M 1.96M 1.79M 3.38M 232M 3.44M 23.05M 9.04M 116M 9.13M 8.9M 384M 234M 2.85M 2.48M 2.31M 2.11M 3.97M 273M 4.05M 27.14M 10.64M 137M 10.75M 10.48M 452M
Logo INSTITUT
Artgen Biotekh PAO is a Russia-based company engaged in the research and development and invesment in biotechnology. The Company develops and implements drugs, products or methods of treatment, diagnostic and prevention of diseases. The Company invests in assets engaged in development and commercialization of new drugs, medical devices, genetic diagnostics and research and other high-tech products and services related to biomedicine and healthcare. Artgen Biotekh PAO develops a platform for startups and companies to share knowledge related to science, research, production, marketing, business, regulations, patent and other fields. Some of the Company's products are Neovasculgen, a gene therapy drug, vaccines Tetraflubet and Betuvax and others.
Employees
-